Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis.
Publication
, Conference
Szmulewitz, RZ; Holzbeierlein, J; Azad, A; Iguchi, T; Villers, A; Alcaraz, A; Alekseev, B; Shore, ND; Rosbrook, B; Zohren, F; Ma, J; Haas, GP ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Szmulewitz, R. Z., Holzbeierlein, J., Azad, A., Iguchi, T., Villers, A., Alcaraz, A., … Armstrong, A. J. (2022). Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Szmulewitz, Russell Zelig, Jeffrey Holzbeierlein, Arun Azad, Taro Iguchi, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, et al. “Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Szmulewitz RZ, Holzbeierlein J, Azad A, Iguchi T, Villers A, Alcaraz A, et al. Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Szmulewitz, Russell Zelig, et al. “Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Szmulewitz RZ, Holzbeierlein J, Azad A, Iguchi T, Villers A, Alcaraz A, Alekseev B, Shore ND, Rosbrook B, Zohren F, Ma J, Haas GP, Gomez-Veiga F, Stenzl A, Armstrong AJ. Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences